WWW - Posts tagged ENZN at BloggingStocks

ENZN posts

Closing Bell: Thinning the Holiday Trading Herd (ENZN, NKE, JPM, AIB, HPQ, AAPL, SIRI)

Posted Dec 22nd 2010 4:00PM by Jon Ogg (RSS feed)
Filed under: Hewlett-Packard (HPQ), Sirius Satellite Radio (SIRI), JPMorgan Chase (JPM), NIKE, Inc'B' (NKE)

Wednesday was the last full day for most of those who are still working this week. Trading volume has already begun to lighten up but we still had several key movers on the day. Retail sales were up at the last minute for those finishing their shopping, GDP revisions for Q3 came in at 2.6% versus a prior 2.5% growth reading, and existing home sales rose by 5.6% in November with an annual sales pace of 4.68 million units.

Here were today's unofficial closing bell levels:

Dow Jones 11,559.49 +26.33 (0.23%)
S&P 500 1,258.83 +4.23 (0.34%)
Nasdaq 2,671.48 +3.87 (0.15%)

Continue reading Closing Bell: Thinning the Holiday Trading Herd (ENZN, NKE, JPM, AIB, HPQ, AAPL, SIRI)

Closing Bell: Bulls gutting bears (ATVI, EWBC, GE, JASO, ENZN, MCD)

Posted Nov 9th 2009 4:00PM by Jon Ogg (RSS feed)

Today was one of those up days that started out strong and ended stronger. The gains were on the heels of overseas buying and on the dollar weakness. The dollar weakness trumped Hurricane Ida's downgrade to a tropical storm when it came to higher oil prices.

Here were today's unofficial closing bell levels:

Dow 10,227.40 +203.98 (2.04%)
S&P 500 1,093.10 +23.80 (2.23%)
Nasdaq 2,154.06 +41.62 (1.97%)

Top Market Rumors
Top Analyst Upgrades & Downgrades
Top Day Trader Alerts

Continue reading Closing Bell: Bulls gutting bears (ATVI, EWBC, GE, JASO, ENZN, MCD)

Icahn eyes Enzon (ENZN): Activist targets biotech

Posted Mar 31st 2008 2:22PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Stocks to Buy

"Carl Icahn - one of Wall Street's most renowned and successful investors - is on another mission; this pitbull is sinking his teeth into one of the companies in our portfolio - Enzon Pharmaceuticals (NASDAQ: ENZN)," notes Marc Lichtenfeld.

In Xcelerated Profits Report, the senior analyst and noted healthcare sector expert takes a look at the small cap biotechnology, which is involved in developing products for the treatment of cancer.

"With an infamous reputation for diving into stocks that he perceives as undervalued and shaking up management teams in order to boost shareholder value, Icahn us one of the best 'business partners' we could have.

"One of the big reasons why we recommended Enzon was because some major institutional investors are clamoring for change at the company. They contend that if Enzon was better at maximizing its true potential, the stock could easily vault from its current undervalued state and generate some real wealth for its shareholders.

Continue reading Icahn eyes Enzon (ENZN): Activist targets biotech